



an Open Access Journal by MDPI

## Marine Compounds and Cancer

Collection Editors:

**Dr. Friedemann Honecker**

Tumor and Breast Center ZeTuP  
St. Gallen, Rorschacherstr. 150,  
9006 St. Gallen, Switzerland

**Dr. Sergey A. Dyshlovoy**

1. Laboratory of Experimental  
Oncology, Department of  
Oncology, Hematology and Bone  
Marrow Transplantation with  
Section Pneumology, Hubertus  
Wald-Tumorzentrum, University  
Medical Center Hamburg-  
Eppendorf, Hamburg, Germany  
2. Martini-Klinik, Prostate Cancer  
Center, University Hospital  
Hamburg-Eppendorf, Hamburg,  
Germany

### Message from the Collection Editors

This Topical Collection will cover the whole scope from agents with cancer-preventive activity, to novel and previously characterized compounds with anti-cancer activity, both in vitro and in vivo, and the latest status of clinical development from drug trials. Notably, compounds possessing pro-carcinogenic activity or mediating cancer cell survival are also within the scope of this Topical Collection. In addition, special focus will be placed on current shortfalls and possible strategies to overcome obstacles in the area of marine anti-cancer drug development.



[mdpi.com/si/2496](https://mdpi.com/si/2496)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Bill J. Baker

Department of Chemistry,  
University of South Florida, 4202  
E. Fowler Ave., CHE 205, Tampa,  
FL 33620-5250, USA

## Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

## Contact Us

---

*Marine Drugs* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/marinedrugs](http://mdpi.com/journal/marinedrugs)  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)  
[X@Marine\\_Drugs](#)